Patents by Inventor Nigel Liverton

Nigel Liverton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxazole orexin receptor antagonists
    Patent number: 9828368
    Abstract: The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: November 28, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Nigel Liverton, Douglas C. Beshore, Scott D. Kuduk, Yunfu Luo, Na Meng, Tingting Yu
  • PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170327490
    Abstract: The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 27, 2015
    Publication date: November 16, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: NIGEL LIVERTON, SCOTT D. KUDUK, DOUGLAS BESHORE, YUNFU LUO, NA MENG, TINGTING XU
  • PYRAZOLE, TRIAZOLE AND TETRAZOLE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170319560
    Abstract: The present invention is directed to pyrazole, triazole and tetrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole, triazole, and tetrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 27, 2015
    Publication date: November 9, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: NIGEL LIVERTON, SCOTT D. KUDUK, DOUGLAS BESHORE, YUNFU LUO, NA MENG
  • AMIDOETHYL AZOLE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170320856
    Abstract: The present invention is directed to amidoethyl azole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: December 18, 2015
    Publication date: November 9, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
  • HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170320884
    Abstract: The present invention is directed to hydroxymethyl piperidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: November 30, 2015
    Publication date: November 9, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
  • 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170320874
    Abstract: The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: December 14, 2015
    Publication date: November 9, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ronald M. Kim, Scott D. Kuduk, Nigel Liverton, Gang Zhou
  • OXAZOLE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170320865
    Abstract: The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 27, 2015
    Publication date: November 9, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: SCOTT D. KUDUK, NIGEL LIVERTON, YUNFU LUO
  • PYRAZOLE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170313684
    Abstract: The present invention is directed to pyrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 27, 2015
    Publication date: November 2, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: NIGEL LIVERTON, SCOTT D. KUDUK, YUNFU LUO
  • PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170313693
    Abstract: The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: September 27, 2015
    Publication date: November 2, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: NIGEL LIVERTON, SCOTT D. KUDUK, YUNFU LUO, NA MENG, TINGTING YU
  • HETEROARYL OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170260136
    Abstract: The present invention is directed to heteroaryl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: December 14, 2015
    Publication date: September 14, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
  • METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170260177
    Abstract: The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: November 30, 2015
    Publication date: September 14, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
  • Thiazole orexin receptor antagonists
    Patent number: 9695163
    Abstract: The present invention is directed to thiazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thiazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: July 4, 2017
    Assignee: MERCK SHARP & DOHME CORP
    Inventors: Nigel Liverton, Douglas C. Beshore, Scott D. Kuduk, Yunfu Luo, Na Meng, Tingting Yu
  • THIAZOLE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20160185768
    Abstract: The present invention is directed to thiazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thiazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 4, 2014
    Publication date: June 30, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: NIGEL LIVERTON, DOUGLAS C. BESHORE, SCOTT D. KUDUK, YUNFU LUO, NA MENG, TINGTING YU
  • OXAZOLE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20160176858
    Abstract: The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 4, 2014
    Publication date: June 23, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: NIGEL LIVERTON, DOUGLAS C. BESHORE, SCOTT D. KUDUK, YUNFU LUO, NA MENG, TINGTING YU
  • HCV NS3 protease inhibitors
    Patent number: 9328138
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 3, 2016
    Assignees: MSD Italia S.R.L., Merck Sharp & Dohme Corp.
    Inventors: Michael T. Rudd, John McCauley, Nigel Liverton, Christiane Grisé-Bard, Marie-Christine Brochu, Sylvie Charron, Virender Aulakh, Benoit Bachand, Patrick Beaulieu, Helmi Zaghdane, Yongxin Han, Marco Ferrara, Steven Harper, Vincenzo Summa, Samuel Chackalamannil, Srikanth Venkatraman, Unmesh Shah, Francisco Velazquez
  • HCV NS3 PROTEASE INHIBITORS
    Publication number: 20140296136
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 2, 2014
    Inventors: Michael T. Rudd, John McCauley, Nigel Liverton, Christiane Grisé-Bard, Marie-Christine Brochu, Sylvie Charron, Virender Aulakh, Benoit Bachand, Patrick Beaulieu, Helmi Zaghdane, Yongxin Han, Marco Ferrara, Steven Harper, Vincenzo Summa, Samuel Chackalamannil, Srikanth Venkatraman, Unmesh Shah, Francisco Velazquez
  • Isoquinolinone potassium channel inhibitors
    Patent number: 8338449
    Abstract: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: December 25, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: B. Wesley Trotter, Christopher Claiborne, Gerald S. Ponticello, Charles J. McIntyre, Nigel Liverton, David A. Claremon
  • Isoquinolinone Potassium Channel Inhibitors
    Publication number: 20100256698
    Abstract: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: April 2, 2010
    Publication date: October 7, 2010
    Applicant: MERCK & CO., INC.
    Inventors: B. Wesley Trotter, Christopher Claiborne, Gerald S. Ponticello, Charles J. McIntyre, Nigel Liverton, David A. Claremon
  • Isoquinoline potassium channel inhibitors
    Patent number: 7763614
    Abstract: The present invention relates to compounds of structural formula I: I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: July 27, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Richard Isaacs, Christopher J. Dinsmore, B. Wesley Trotter, Nigel Liverton, Douglas C. Beshore, Nathan R. Kett, Charles J. McIntyre, Kausik K. Nanda, David A. Claremon
  • Isoquinolinone potassium channel inhibitors
    Patent number: 7723352
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: May 25, 2010
    Assignee: Merck Sharp & Dohme
    Inventors: B. Wesley Trotter, Christopher Claiborne, Gerald S. Ponticello, Charles J. McIntyre, Nigel Liverton, David A. Claremon